Lateral CAR T-Cell Platform
Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.
Lateral CAR T-Cell Platform
Founded to translate 20 years of pioneering Chimeric Antigen Receptor T-Cell (CAR-T) research led by Dr John Maher at King's College London (KCL), Leucid Bio has developed a proprietary Lateral CAR platform that builds upon Dr Maher’s novel novel CAR-T model in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. This technology gives properties to the CAR-T enabling them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.
Lead asset - LEU011
LEU011 is a lateral CAR targeting NKG2D ligands. Currently in pre-clinical development for the treatment of solid tumours and haematological malignancies. The NKG2D receptor is an activating immune receptor that triggers cell death upon recognition of one or more of the eight human NKG2D ligands expressed on transformed, infected or damaged cells.